Ranbaxy Laboratories is currently trading at Rs. 643.65, up by 5.35 points or 0.84% from its previous closing of Rs. 638.30 on the BSE.
The scrip opened at Rs. 643.90 and has touched a high and low of Rs. 644.95 and Rs. 641.00 respectively. So far 6,691 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 667.30 on 03-Sep-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.
Last one week high and low of the scrip stood at Rs. 647.00 and Rs. 552.80 respectively. The current market cap of the company is Rs. 27,291.00 crore.
The promoters holding in the company stood at 63.40% while Institutions and Non-Institutions held 20.53% and 13.65% respectively.
Ranbaxy Laboratories’ wholly owned subsidiary - Ranbaxy Laboratories Inc. (RLI), has launched ABSORICA (isotretinoin) 25mg and 35mg capsules into the US healthcare market. ABSORICA has become the most prescribed branded oral isotretinoin in the US, as per a recent independent survey conducted with dermatologists.
The product is licensed by Ranbaxy from Cipher Pharmaceuticals, Inc. It is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1515.70 |
Dr. Reddys Lab | 6225.50 |
Cipla | 1410.85 |
Zydus Lifesciences | 955.75 |
Lupin | 1655.60 |
View more.. |